The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with a panel Q&A discussion with live audience participation. 

The panelists, Gail J. Roboz, Jorge Sierra, and Jorge Cortes, shared their perspectives on treatment decisions for patients with FLT3-mutated acute myeloid leukemia, including choice of FLT3 inhibitor, how FLT3-mutated measurable residual disease (MRD) might guide transplant decisions, as well as the importance of monitoring FLT3-mutated MRD with the appropriate assay. 

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.